Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express

03/19

Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:

• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.

• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.

The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.

The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1161078965"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161078965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161078965?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161078965","market":"us","top_or_hot":-1,"title":"Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:</p>\n<p>• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.</p>\n<p>The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-19 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:</p>\n<p>• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.</p>\n<p>The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1161078965","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161078965","pubTimestamp":1773909795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include: • Approval and publication of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药(00460)定于2026年3月31日召开董事会批准2025财年业绩并考虑末期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:\n• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.\n• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.\nThe meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.\nThe company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}